IOP substantially reduced through 5 years in patients with OAG after iStent inject implantation

Posted on

Implantation with a second-generation trabecular micro-bypass stents (iStent inject) substantially reduced IOP in patients with open-angle glaucoma (OAG) through 5 years, according to a presentation at the 38th Congress of the European Society of Cataract and Refractive Surgeons.

In this 5-year prospective study, 57 patients (57 eyes) with OAG being treated with 1 preoperative medication, underwent implantation. Efficacy outcomes included ≥ 20% IOP reduction versus baseline and IOP ≤ 18 mmHg.

In more than 80% of eyes, IOP endpoints were achieved at 5 years with no medication.

Mean IOP decreased by 47% to 12.9 mmHg compared to pre-op washout IOP 24.4 ± 1.3 at 5 years. More than 90% of eyes remained medication-free throughout follow-up.

No intraoperative or device-related adverse events were recorded.


Aptel F, et al. Sustained 5-year safety and IOP outcomes in open-angle glaucoma subjects treated with trabecular micro-bypass stents. Presented at: 38th Congress of the European Society of Cataract and Refractive Surgeons, October 2-4, 2020.

Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021